“…The SNP in the gene BDNF, BDNFVal66Met, is one example, among many, of an interesting candidate to explore for influencing chemotherapeutic impact and secondary effects across development. This SNP in the BDNF gene has been associated with altered susceptibility to a variety of neuropsychiatric disorders including anxiety and depression in adults (Frielingsdorf et al, 2010; Gatt et al, 2009; Gratacos et al, 2007; Jiang et al, 2005; Momose et al, 2002; Sen et al, 2003; Sklar et al, 2002; Ventriglia et al, 2002) and more recently has been shown to influence PTSD symptoms and cortical thickness in childhood trauma (Jin et al, 2019). This valine-to-methionine substitution at position 66 of the BDNF prodomain alters normal interactions with the sorting protein, sortilin, resulting in altered trafficking of BDNF into the regulated secretory pathway, which leads to an approximate 30% decrease in activity-dependent release (Chen et al, 2005, 2006; Chen et al, 2004; Egan et al, 2003).…”